PMV Pharmaceuticals (PMVP) Total Non-Current Liabilities (2019 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly Total Non-Current Liabilities came in at $8.6 million in Q1 2026, down 18.15% YoY from $10.5 million in Q1 2025, and down 27.47% on a QoQ basis from $11.8 million in Q4 2025.
PMV Pharmaceuticals (PMVP) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 5 years of Total Non-Current Liabilities data on file, last reported at $8.6 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 18.15% year-over-year to $8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.6 million (down 18.15% YoY) and the FY2025 annual result came in at $11.8 million, down 22.08% from the prior year.
- Total Non-Current Liabilities declined to $8.6 million in Q1 2026, from $11.8 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $26.5 million in Q4 2023 to a low of $8.6 million in Q1 2026.
- A 4-year average of $18.2 million and a median of $19.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities gained 9.28% — and 2025, when it slumped 56.61%.
- Tracing PMVP's Total Non-Current Liabilities over 4 years: stood at $26.5 million in 2023, then tumbled by 42.53% to $15.2 million in 2024, then retreated by 22.08% to $11.8 million in 2025, then fell by 27.47% to $8.6 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $8.6 million (Q1 2026), $11.8 million (Q4 2025), and $12.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | PMV Pharmaceuticals | 70.74 Mn | -8.69 Mn | - | 10.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.60 Mn |
| Dec 31, 2025 | 11.85 Mn |
| Sep 30, 2025 | 12.85 Mn |
| Jun 30, 2025 | 12.25 Mn |
| Mar 31, 2025 | 10.50 Mn |
| Dec 31, 2024 | 15.21 Mn |
| Sep 30, 2024 | 25.59 Mn |
| Jun 30, 2024 | 23.22 Mn |
| Mar 31, 2024 | 24.20 Mn |
| Dec 31, 2023 | 26.46 Mn |
| Sep 30, 2023 | 23.42 Mn |
| Jun 30, 2023 | 24.41 Mn |
| Dec 31, 2019 | 4.52 Mn |